Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

ATXN7 Antikörper (AA 354-381)

ATXN7 Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN5532827
  • Target Alle ATXN7 Antikörper anzeigen
    ATXN7 (Ataxin 7 (ATXN7))
    Bindungsspezifität
    • 15
    • 7
    • 7
    • 6
    • 6
    • 6
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 354-381
    Reaktivität
    • 34
    • 27
    • 19
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    Human
    Wirt
    • 48
    • 1
    Kaninchen
    Klonalität
    • 48
    • 1
    Polyklonal
    Konjugat
    • 15
    • 5
    • 4
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser ATXN7 Antikörper ist unkonjugiert
    Applikation
    • 38
    • 23
    • 13
    • 13
    • 4
    • 3
    • 3
    • 2
    • 2
    • 1
    Western Blotting (WB)
    Aufreinigung
    This antibody is purified through a protein A column, followed by peptide affinity purification.
    Immunogen
    This ATXN7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 354-381 amino acids from the Central region of human ATXN7.
    Isotyp
    Ig Fraction
    Top Product
    Discover our top product ATXN7 Primärantikörper
  • Applikationshinweise
    For WB starting dilution is: 1:1000
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    0.5 mg/mL
    Buffer
    Supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
  • Target
    ATXN7 (Ataxin 7 (ATXN7))
    Andere Bezeichnung
    ATXN7 (ATXN7 Produkte)
    Synonyme
    MGC82940 antikoerper, ADCAII antikoerper, OPCA3 antikoerper, SCA7 antikoerper, A430107N12Rik antikoerper, AI627028 antikoerper, Sca7 antikoerper, ataxin-7 antikoerper, RGD1562692 antikoerper, ataxin 7 L homeolog antikoerper, ataxin 7 antikoerper, atxn7.L antikoerper, atxn7 antikoerper, ATXN7 antikoerper, Atxn7 antikoerper
    Hintergrund
    The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the 'pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with spinocerebellar ataxia-7 contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The encoded protein is a component of the SPT3/TAF9/GCN5 acetyltransferase (STAGA) and TBP-free TAF-containing (TFTC) chromatin remodeling complexes, and it thus plays a role in transcriptional regulation. Alternative splicing results in multiple transcript variants.
    Molekulargewicht
    95 kDa
    Gen-ID
    6314
    UniProt
    O15265
Sie sind hier:
Kundenservice